focus -WSS

focus

author：explore 2025-09-30 00:36:14 - browse：9792

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Group opposing PBM reform sets lobbying record

WSS

Change Healthcare: What is it, why does its cyberattack matter?

Startup Neumora takes a novel depression drug to Phase 3

Medicare to cover more brain scans for Alzheimer’s patients

Why Talkspace is targeting Medicare, a tricky market

Medicare drug price negotiation hearing pits pharma v Biden admin

WHO calls for emergency meeting on new China virus, as cases spread

knowledge

focus

explore

Hollywood unions extend contract negotiations for actors

As digital health tech proliferates, a new institute aims to cut through hype

Moonlake's readout produced a cash windfall. Risks remain

Harvard's David Sinclair gets blowback over aging

Apple is now the first public company to be valued at $3 trillion

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

Medicare details structure of new drug price negotiation program

AI can’t replace a physician’s gut feeling

The cancer drug shortage isn’t new — and neither are the solutions

Key House panel plots a new health care package

hotspot

Stem cell biologist probes earliest stages of human development

How dance can help nurses traumatized by Covid

Stem cell biologist probes earliest stages of human development

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

How Medicaid coverage policies for immigrants impact new moms

Microsoft's Peter Lee: Generative AI could help doctors be more human

hotspot

Wikipedia

focus

knowledge